Bettering the Lives of People Impacted by Kidney Disease John Butler, CEO January 2025 1 NASDAQ: AKBA Cautionary note on forward-looking statements 3 Leading commercial-stage company focused on kidney disease Vafseo® (vadadustat) launched as treatment for anemia due to chronic kidney disease for adult patients on dialysis ~$1billion U.S. market opportunity in dialysis patient population1 Statements in this presentation regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectatio ...